Whilst most of
the science blogosphere my science blogging colleagues were getting stuck in to Science Online London 2012, I was at the closing plenary of the 62nd meeting of the American Society of Human Genetics. If solo12 is the home of science online in London, ASHG2012 was an example of science online in action: the use of social media to share and discuss cutting-edge genetics research.
Chris Gunter, @girlscientist, is a member of the ASHG 2012 Program Committee and chair of the ASHG Communications Committee. It is thanks to her drive that the infrastructure was in place for social media to be used to enhance the experience of the conference, both for attendees and for those who could not make it in person. The conference program detailed social media guidelines. Presentations were tweetable and shareable unless the speaker requested otherwise, and the conference hashtag, #ASHG2012, was a source of summaries of talks as they were delivered. Early in the conference, Daniel MacArthur, @dgmacarthur, tweeted his ten guidelines for tweeting at conferences. A social media workshop formed part of the program.
The conference app contains the schedule together with poster and presentation abstracts and space for taking notes. This was useful for planning and navigating a busy week. The Society twitter feed, @GeneticsSociety, kept attendees updated with program highlights and any changes, although it was not flawless and confused jetlagged geneticists further by tweeting to kick off the closing plenary in the wee small hours of the morning, in error.
Mishaps aside, social media was a definite presence at this meeting, from the tweetup on the first night to the crowdsourced questions to the panel at the closing plenary. I hope that social medial continues to be integrated into future meetings, both at ASHG and beyond.
The ASHG meeting is vast. This 62nd meeting was bigger by a factor of fifteen than the largest meeting I had attended previously. Registrants topped out at nearly seven thousand, a small town’s worth of geneticists and several hundred companies represented. As is often then way with conferences the highlights for me were the people I met. The quality of the talks was high, and the organisation of the conference was slick. I attended a variety of sessions.
The data presented in the session on pharmacogenomics represented the first steps on the road towards personalised medicine. The session opened with a discuss of the topics of ancestry and genetic variation that I had discussed earlier in the meeting. Edward Ramos gave an overview, including a quotation found in a paper by him and his colleague Charles Rotimi, which forms a coherent answer to the debate that I took part in a few days before:
If we use genomic information correctly, we will simultaneously describe our similarities and differences without reaffirming old prejudices. More importantly, the careful unbiased study and interpretation of the human story coded in our DNA will enable us to appreciate the fact that individuals cannot be treated as a representative for all those who physically resemble them or who share some of their ancestry. The human genome is a mosaic of our experiences, past and present.
The session continued with a focus on clinical applications. Genetic mutations, often in drug-metabolising genes, can result in large variation in how patients react to a drug. A drug that is otherwise beneficial could cause severe side-effects, or even death, in patients carrying those mutations. Being able to identify the relevant variants means that dosage could be adjusted, or an alternative treatment found, for affected individuals. Examples were presented from a clinical trial where this principal was used to demonstrate that genotyping patients and giving tailored treatment advice reduced side effects in mutant individuals.
At ASHG2012’s closing plenary, attendees reflected on progress in human genetics research in recent years. Wordclouds of the abstracts presented at meetings past and present showed the subtle but meaningful shifts, for example from genome-wide association studies to whole genome sequencing. The meeting was summarised by a quotation that resonates with the research I have been doing as part of my PhD, and which implicitly describes the important challenges in human genetics research for for the coming years. As a statistical geneticist, I was reassured that I will be kept busy in the future. The meeting concluded:
Ability to identify variation is no longer the limiting step in our field.